Abstract

BackgroundArdisia crispa (Thunb.) A.DC (Primulaceae), is a medicinal herb traditionally used by Asian people as remedies to cure inflammatory related diseases, including rheumatism. The plant roots possess various pharmacological activities including antipyretic, anti-inflammation and antitumor. Previous phytochemical studies of the plant roots have identified long chain alkyl-1,4-benzoquinones as major constituents, together with other phytochemicals. Hexane fraction of the plant roots (ACRH), was previously reported with anti-angiogenic and anti-arthritic properties, while its effect on their anti-arthritic in vitro, is yet unrevealed. Considering the significance of angiogenesis inhibition in developing new anti-arthritic agent, thus we investigated the anti-arthritic potential of Ardisia crispa roots by suppressing angiogenesis, in vitro.MethodsArdisia crispa roots hexane extract (ACRH) was prepared from the plant roots using absolute n-hexane. ACRH was fractionated into quinone-rich fraction (QRF) and further isolated to yield benzoquinonoid compound (BQ), respectively. In vitro experiments using VEGF-induced human umbilical vein endothelial cells (HUVECs) and IL-1β-induced human fibroblast-like synoviocytes for rheumatoid arthritis (HFLS-RA) were performed to evaluate the effects of these samples on VEGF-induced HUVECs proliferation and tube formation, and towards IL-1β-induced HFLS-RA proliferation, invasion, and apoptosis, respectively. Therapeutic concentrations (0.05, 0.5, and 5 μg/mL) tested in this study were predetermined based on the IC50 values obtained from the MTT assay.ResultsACRH, QRF, and BQ exerted concentration-independent antiproliferative effects on VEGF-induced HUVECs and IL-1β-induced HFLS-RA, with IC50 values at 1.09 ± 0.18, 3.85 ± 0.26, and 1.34 ± 0.16 μg/mL in HUVECs; and 3.60 ± 1.38, 4.47 ± 0.34, and 1.09 ± 0.09 μg/mL in HFLS-RA, respectively. Anti-angiogenic properties of these samples were verified via significant inhibition on VEGF-induced HUVECs tube formation, in a concentration-independent manner. The invasiveness of IL-1β-induced HFLS-RA was also significantly inhibited in a concentration-independent manner by all samples. ACRH and BQ, but not QRF, significantly enhanced the apoptosis of IL-1β-induced HFLS-RA elicited at their highest concentration (5 μg/mL) (P < 0.05).ConclusionsThese findings highlight the bioactive fractions and compound from Ardisia crispa roots as potential anti-arthritic agents by inhibiting both HUVECs and HFLS-RA’s cellular functions in vitro, possibly mediated via their anti-angiogenic effects.

Highlights

  • Ardisia crispa (Thunb.) A.DC (Primulaceae), is a medicinal herb traditionally used by Asian people as remedies to cure inflammatory related diseases, including rheumatism

  • In this study, we aimed to investigate the antiarthritic potential of Ardisia crispa roots hexane fraction and its benzoquinone constituent mediated by their targeted inhibition on angiogenic human umbilical vein endothelial cells (HUVECs) and human fibroblast-like synoviocytes for rheumatoid arthritis (HFLS-Rheumatoid arthritis (RA)) cellular functions in vitro

  • Chemical and reagents Human umbilical vein endothelial cells (HUVECs) and endothelial cell medium (ECM) were purchased from ScienCell, USA; Human fibroblast-like synoviocytes for rheumatoid arthritis (HFLS-RA) and synoviocytes growth medium (SGM) were supplied by Cell Applications INC (USA); VEGF165 and Interleukin 1-beta (IL-1β) were purchased from Sigma-Aldrich, USA; Suramin hexasodium salt and dimethyl sulfoxide (DMSO) were obtained from Abcam, UK; 3-(4, 5

Read more

Summary

Introduction

Ardisia crispa (Thunb.) A.DC (Primulaceae), is a medicinal herb traditionally used by Asian people as remedies to cure inflammatory related diseases, including rheumatism. Considering the significance of angiogenesis inhibition in developing new anti-arthritic agent, we investigated the anti-arthritic potential of Ardisia crispa roots by suppressing angiogenesis, in vitro. Biologic DMARDs have revolutionized the treatment of arthritis to treat-to-target approach These treatment options are challenging as their application need proper consideration between their efficacies and the treatmentspecific side effects [5]. Angiogenesis, a process in which new vessels sprouting from preexisting vasculature, is a potential target for therapeutic interventions in RA [6]. It is commonly a physiological process at its equivocal balance, such as organ development, tissue repair, and reproduction. As strong correlations exist between angiogenesis and RA; many anti-arthritic drugs currently in the phase of development are designed to target angiogenesis inhibition for RA therapeutics [10]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call